EpiCat is Blackstone Labs’ Epicatechin based muscle-builder. Although it contains two other ingredients, Green Tea Extract and Ribe Fiber, Epicatechin is clearly the main attraction, so we’ll just focus on that for the purpose of this review…FIND IT HERE
Epicatechin is a flavonol alleged to inhibit Myostatin, a type of myokine (signaling protein released by muscle fibers) which suppresses muscle growth. The opposite of Myostatin is Follistatin, a signaling protein which induces muscle growth by blocking Myostatin.
A 2014 study, published in “The Journal of Nutritional Biochemistry”, found that 7 days of Epicatechin supplementation (150mg daily) was able to favorably influence the Follistatin/Myostatin ratio and subjects showed a 7% in hand grip strength.
Although the results of this study certainly indicate a role for Epicatechin in promoting muscle growth, muscle mass was not actually measured (because of the short duration of the study). So, rather than considering this study conclusive, it should be viewed as strictly preliminary. Until longer-term human studies are conducted, we won’t know the degree to which Epicatechin actually influences muscle growth.
Blackstone Labs does not disclose the exact dose of Epicatechin present in EpiCat. However, given that the entire proprietary blend is 1g, there is no reason to suspect that Epicatechin is under-dosed.
THE BOTTOM LINE
Since the exact amount of Epicatechin is unknown, its tough to gauge the overall efficacy of the EpiCat formula. Blackstone Labs doesn’t seem to be in any hurry to make the switch over to transparent labels. That said, there doesn’t seem to be any red flags with regards to dosing, so EpiCat may very well be effective…we just can’t be completely sure.
If you’re looking for something that will actually help you gain lean muscle, check out our Best Muscle Builders List!
- Gutierrez-Salmean, Gabriel, et al. “Effects of (−)-epicatechin on molecular modulators of skeletal muscle growth and differentiation.” The Journal of nutritional biochemistry 25.1 (2014): 91-94.